Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome
Phase 4
Completed
- Conditions
- HypertensionMetabolic Syndrome
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00241150
Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance
Phase 4
Completed
- Conditions
- HypertensionImpaired Glucose Tolerance
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 27
- Registration Number
- NCT00241072
Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1099
- Registration Number
- NCT00241124
A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3790
- Registration Number
- NCT00241137
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
Phase 4
Completed
- Conditions
- PROTEINURIAHypertensionType 2 Diabetes
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 392
- Registration Number
- NCT00241085
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 836
- Registration Number
- NCT00241007
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients
Phase 4
Completed
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 183
- Registration Number
- NCT00241059
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
Phase 4
Completed
- Conditions
- HypertensionCongestive Heart Failure
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 37
- Registration Number
- NCT00241098
Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients
Phase 4
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 79
- Registration Number
- NCT00240955
Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women
Phase 4
Completed
- Conditions
- Forearm Fracture
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2006-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00239889
- Locations
- 🇨🇭
Novartis, Basel, Switzerland